EA201070713A1 - Твердые лекарственные формы - Google Patents

Твердые лекарственные формы

Info

Publication number
EA201070713A1
EA201070713A1 EA201070713A EA201070713A EA201070713A1 EA 201070713 A1 EA201070713 A1 EA 201070713A1 EA 201070713 A EA201070713 A EA 201070713A EA 201070713 A EA201070713 A EA 201070713A EA 201070713 A1 EA201070713 A1 EA 201070713A1
Authority
EA
Eurasian Patent Office
Prior art keywords
androstan
ethynyl
solid
diol
formulations
Prior art date
Application number
EA201070713A
Other languages
English (en)
Other versions
EA018974B1 (ru
EA018974B9 (ru
Inventor
Стивен К. Вайт
Двайт Стикни
Эрин Олсон
Кейт Р. Лоример
Брентон С. Вулф
Original Assignee
Харбор Биосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Харбор Биосайенсиз, Инк. filed Critical Харбор Биосайенсиз, Инк.
Publication of EA201070713A1 publication Critical patent/EA201070713A1/ru
Publication of EA018974B1 publication Critical patent/EA018974B1/ru
Publication of EA018974B9 publication Critical patent/EA018974B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

В изобретении предложен и описан твердый 17α-этинил-5α-андростан-3α,17β-диол, в том числе, его аморфные и кристаллические формы и конкретные полиморфные формы. Ангидриды и сольваты 17α-этинил-5α-андростан-3α,17β-диола включают ангидрид в форме III и сольват в форме I. Изобретение также относится к твердым и суспензионным составам, содержащим 17α-этинил-5α-андростан-3α,17β-диол в описанной твердой форме, и применению этих составов для лечения у субъектов или пациентов-людей раков или предраковых состояний, таких как рак предстательной железы или рак молочной железы. Изобретение также относится к способам получения жидких составов из твердых форм 17α-этинил-5α-андростан-3α,17β-диола и применению таких составов при лечении описанных состояний.
EA201070713A 2008-02-05 2009-02-05 Твердые лекарственные формы EA018974B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US9369408P 2008-09-02 2008-09-02
PCT/US2009/033280 WO2009100258A1 (en) 2008-02-05 2009-02-05 Pharmaceutical solid state forms

Publications (3)

Publication Number Publication Date
EA201070713A1 true EA201070713A1 (ru) 2011-08-30
EA018974B1 EA018974B1 (ru) 2013-12-30
EA018974B9 EA018974B9 (ru) 2014-04-30

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070713A EA018974B9 (ru) 2008-02-05 2009-02-05 Твердые лекарственные формы

Country Status (11)

Country Link
US (4) US8518922B2 (ru)
EP (1) EP2249838A4 (ru)
JP (1) JP2011511011A (ru)
KR (1) KR20100113602A (ru)
CN (2) CN101939009B (ru)
AU (1) AU2009212314C1 (ru)
CA (1) CA2712005C (ru)
EA (1) EA018974B9 (ru)
HK (1) HK1147695A1 (ru)
IL (1) IL207378A0 (ru)
WO (1) WO2009100258A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527986A (ja) * 2008-04-03 2011-11-10 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬の固体状態形態
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012083161A1 (en) * 2010-12-17 2012-06-21 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
RU2016122882A (ru) * 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
AU2016370499B2 (en) 2015-12-15 2022-06-30 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
AU2018246257B2 (en) * 2017-03-30 2022-05-12 Merck Patent Gmbh Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
KR20210111254A (ko) 2018-11-30 2021-09-10 캐리스 엠피아이, 아이엔씨. 차세대 분자 프로파일링
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
ES2134267T3 (es) 1992-08-28 1999-10-01 Bone Care Int Inc 1alfa,24(s)-dihidroxi vitamina d2, su preparacion y utilizacion.
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
DE69736704T2 (de) 1996-03-29 2007-09-13 Duphar International Research B.V. Piperazin- und piperidin- derivate
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ES2327538T3 (es) 2000-12-14 2009-10-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Proceso para preparar productos de hormona esteroidea que comprenden un agente estabilizante en forma no cristalina.
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TW200730505A (en) * 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
HUE042925T2 (hu) * 2006-04-22 2019-07-29 Neurmedix Inc Gyógyszerek és alkalmazások
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
US20130345184A1 (en) 2013-12-26
US20130338125A1 (en) 2013-12-19
JP2011511011A (ja) 2011-04-07
CN101939009B (zh) 2013-07-17
AU2009212314A1 (en) 2009-08-13
CA2712005C (en) 2014-04-15
EP2249838A1 (en) 2010-11-17
EP2249838A4 (en) 2012-05-02
EA018974B1 (ru) 2013-12-30
CA2712005A1 (en) 2009-08-13
US20130345455A1 (en) 2013-12-26
US9314471B2 (en) 2016-04-19
AU2009212314C1 (en) 2014-05-08
EA018974B9 (ru) 2014-04-30
KR20100113602A (ko) 2010-10-21
AU2009212314B2 (en) 2013-11-21
IL207378A0 (en) 2010-12-30
US20090291932A1 (en) 2009-11-26
CN103467554A (zh) 2013-12-25
US8518922B2 (en) 2013-08-27
WO2009100258A1 (en) 2009-08-13
CN101939009A (zh) 2011-01-05
HK1147695A1 (en) 2011-08-19

Similar Documents

Publication Publication Date Title
EA201070713A1 (ru) Твердые лекарственные формы
PH12019501792A1 (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
MX2012007013A (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EA201071250A1 (ru) Композиции и методы для лечения рака молочной железы
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
SG171583A1 (en) Composition for the treatment of resistant cancers comprising oridonin
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
MX2018001965A (es) Formulaciones liquidas que contienen picosulfato y citrato de magnesio.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
EP2073635A4 (en) MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU